Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market Undervaluation
Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
GlobalData on MSN1d
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...
Syndax falls after mid-stage data for leukemia drug
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Promising Market Potential and Efficacy of Syndax Pharmaceuticals’ Revumenib Justify Buy Rating
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...
FierceBiotech2d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...
The Pharma Letter1d
Syndax shares slide despite pivotal trial success
Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 5, 2024 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.98, expectations were $-1.13. Operator: Good day, everyone, and welcome ...
bovnews7d
What’s Causing Syndax Pharmaceuticals Inc (SNDX) Stock’s -4.60% Drop Over the Last Six Months?
On Wednesday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $21.35 which represents a slight increase of $1.66 or 8.43% from the prior close of $19.69. The stock ...